VECTUS BIOSYSTEMS LIMITED — AGM Information 2024

Nov 26, 2024

ABN 54 117 526 137

==> picture [155 x 56] intentionally omitted <==

Vectus Biosystems Limited

Chairman’s Address to the 27 November 2024 Annual General Meeting

On 24 May 2024 Vectus sadly reported the passing of its co-founder and Chief Executive Officer, Dr Karen Duggan, who, for 18 years, led the Company in an attempt to meet the challenge of prevention and treatment of cardiovascular fibrosis. The Board’s sincere gratitude goes to Karen and the Vectus team for their work during the 2023-24 financial year in moving the Company’s lead compound, VB0004, through the important Phase Ia and Ib human trials.

The 2024 year saw Vectus achieve a number of important milestones, commencing with the April 2024 finalisation of the Phase Ib human safety clinical trial in collaboration with the Nucleus Network in Melbourne and Scientia Clinical Research in Sydney, and Syneos Health. No significant adverse events were reported in the Phase Ia or Phase Ib human trials. The Company’s lead cardiovascular candidate, VB0004, is supported by a broad portfolio of issued patents. Vectus’ strategy is to develop and perform early validation of its drug candidates to the point where they become commercially attractive to potential pharmaceutical partners. The Company’s objective is to then partner with one or more companies via a licencing programme, focusing initially on VB0004, together with advancing its other drug candidates A32, A79 and P5 from its extensive drug library. Success in licencing any one of the lead compounds in Vectus’ drug library could represent a major uplift in shareholder value and help generate additional opportunities.

The Company’s drugs are targeting some of the largest pharmaceutical franchises in the world. Vectus is working closely with C14 Consulting Group, LLC in the USA, who will be joining us today, under its exclusive mandate to lead and manage the programme of potential licencing, or a joint venture, or both, of the Company’s portfolio of patented small therapeutic molecules, including the human lead compound VB0004. Vectus and C14 have developed new information documentation that is in line with the needs of a broad range of pharmaceutical companies and potential collaborators. C14 is a highly-regarded consultancy with a global capability.

Fibrotic diseases account for a significant percentage of the world’s current mortality rate. I see, in my work as a Radiologist and Clinical Physician, the real need for this new class of drugs, providing substantial social, patient and health economic outcomes. Fibrosis, or scar tissue, is the end point of a whole host of diseases, including high blood pressure, following myocardial infarction, traumatic injury, post infections (such as COVID-19), radiotherapy and silicosis. To have potential drugs, like those in the Company’s stable, that can not only stop the growth of scar tissue, but also reverse the fibrosis, is a major development in medicine. One of the many innovations of Vectus has been the successful development of small molecule, orally dosable drugs from the native peptides, into the form most common in today’s drug presentations.

Finance

The funds expended by the Company during the last year were largely in connection with the finalisation of the Phase Ia and Ib human clinical trials for VB0004. Cash-on-hand at 31 October 2024 was $936,000. Vectus has dramatically lowered its operating costs whilst maintaining its intellectual property and patent library, which are now the Company’s primary focus in commercialising. I am

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137 Unit 5, Ground Floor, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia Telephone: +61 2 8344 1300, Facsimile: +61 2 9697 0944 Email: info@vectusbiosystems.com.au Website: www.vectusbiosystems.com.au

ABN 54 117 526 137

==> picture [80 x 29] intentionally omitted <==

pleased to report that engagement with well-known pharmaceutical companies has been expanded and today Martina Molsbergen from C14 will be providing some insight into this process.

Accugen

Accugen is one of Vectus’ assets that will be made available to the industry to commercialise, subject to finding suitable licencees. The Accugen technology is aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Conclusion

I take this opportunity to thank the Company’s team and its Board for their significant contribution to take Vectus to the point where an expanded commercialisation programme is now underway. Dr Susan Pond, who joined the Board in May 2016 and who retires at the end of this AGM, has been a contributor to this process. We wish Susan well in her retirement.

The Company is currently in discussions in relation to the appointment of an additional Non-Executive Director and Vectus anticipates an announcement in the near term. I take this opportunity to express our sincere thanks to the Company’s exceptional advisers that have stepped in to help Vectus through this challenging period. Finally, I thank the Company’s shareholders for their support during this exciting and challenging year in Vectus’ development. We look forward to the partnership with C14 in advancing the commercialisation of the Company’s unique library of first-in-class drug assets and, in parallel, we are committed to the goal of advancing the healthcare of patients around the world and, in doing so, benefiting our stakeholders.

Vectus Biosystems Limited

Ron Shnier

Chairman

==> picture [363 x 344] intentionally omitted <==

----- Start of picture text -----

C14 Consulting
Group
For the Business of Life
Sciences
----- End of picture text -----

November 2024 Company Presentation

www.c14consultingroup.com

Martina Molsbergen

CEO, C14 Consulting Group

+34 years of business development, marketing, and entrepreneurial experience including 24 years of business development experience in biotherapeutics and antibodies

Proven corporate development strategy and leadership experience within large and small company settings closing + 500 deals and creating over $5B in transactions

==> picture [243 x 340] intentionally omitted <==

Recipient of 4 Presidents’ Awards

Exceptional Knowledge

Broad access to academia and industry

==> picture [84 x 83] intentionally omitted <==

Business & Investment Strategy

C14 is built on a large pedigree of former industry executives with proven track records of success

==> picture [83 x 83] intentionally omitted <==

Deal Making

==> picture [84 x 84] intentionally omitted <==

Scientific Evaluation

Pedigree Team & Access to KOLs

==> picture [70 x 69] intentionally omitted <==

==> picture [69 x 69] intentionally omitted <==

Large team of execs, scouts, Strong competence and heads of R&D, and KOLs technical expertise in protein (MD, Ph.D.) chemistry and drug with +20 years industry discovery/development experience PhD/MS/MD

==> picture [68 x 69] intentionally omitted <==

C14 Team offers:

✓ High-value

• ✓ Trained Effective and Reliable

• ✓ Cost Saving ✓ Efficient

Deal Making Success Proven Track Record is Core Competence

Out licensing focused (“sell” side), negotiations, transactions and strategic alliance management history

Affiliated with many Societies Frequent Discovery, Clinical Development, Investment and Partnering meetings Recognized as the “go to” source for biologics and representing only Quality companies

Plethora of deals spanning discovery, clinical and commercial

Leverage C- level contacts within many companies

Large network spanning the globe

==> picture [394 x 105] intentionally omitted <==

Large Experience Base

==> picture [138 x 137] intentionally omitted <==

Life Science Sectors Pharmaceuticals Diagnostics Immunology Biologics Vaccines Platform Technologies

==> picture [215 x 125] intentionally omitted <==

Therapeutic Areas Cardiology CNS Dermatology Immunology Infectious Disease Oncology Pain & Inflammatory Disease Respiratory Disease Women ’ s Health Urology

==> picture [137 x 137] intentionally omitted <==

Geographic Experience North America South America Europe Asia Australia Japan

Strategy Refinement

Work with clients to develop a blueprint strategy for optimally positioning & maximizing the value of any deal

Evaluate client’s current capabilities and desired goals for future growth; identify competitive strengths, capital needs & exit strategies Identify partners, clarify preferred models , develop presentations

==> picture [367 x 316] intentionally omitted <==

Specialized in business development & investment strategies for platform technologies & products

Business Development Planning

✓ Determine best selling features for differentiation

✓ Target list of potential clients

✓ Outreach through existing network/ licensing and scientific meetings/ publications/ sponsorships

✓ Competitive intelligence

✓ Drive decision making to result in deals

✓ Creative deal making required/ showcasing of assets

Generating, Accelerating & Expanding Transactional Opportunities

✓ Sourcing, structuring and executing transactional opportunities

• ✓ Creating optimal deal structures: Licensing, Partnering, M&A

• ✓ Asset acquisition and divestiture

• ✓ Creating venturing capabilities

• ✓ Corporate formation and structuring

• ✓ Valuation and corporate/asset repositioning

• ✓ Fundraising preparation

• ✓ Strategic advisory

==> picture [435 x 403] intentionally omitted <==

Contact Information:

Martina Molsbergen, CEO mmolsbergen@c14consultinggroup.com www.c14consultinggroup.com O: (610) 644-2243 M: (610) 291-2726

Thank you!

Appendix

Representative Clients Large Clients

==> picture [127 x 55] intentionally omitted <==

==> picture [134 x 43] intentionally omitted <==

==> picture [133 x 31] intentionally omitted <==

==> picture [126 x 34] intentionally omitted <==

==> picture [134 x 45] intentionally omitted <==

==> picture [178 x 58] intentionally omitted <==

==> picture [193 x 24] intentionally omitted <==

==> picture [99 x 54] intentionally omitted <==

==> picture [179 x 56] intentionally omitted <==

==> picture [179 x 39] intentionally omitted <==

==> picture [99 x 61] intentionally omitted <==

==> picture [86 x 45] intentionally omitted <==

==> picture [161 x 29] intentionally omitted <==

==> picture [151 x 53] intentionally omitted <==

==> picture [187 x 30] intentionally omitted <==

Representative Clients

Early/Mid stage Clients

==> picture [98 x 44] intentionally omitted <==

==> picture [92 x 24] intentionally omitted <==

==> picture [93 x 36] intentionally omitted <==

==> picture [85 x 35] intentionally omitted <==

==> picture [44 x 49] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [103 x 31] intentionally omitted <==

==> picture [127 x 27] intentionally omitted <==

==> picture [110 x 16] intentionally omitted <==

==> picture [147 x 41] intentionally omitted <==

==> picture [857 x 236] intentionally omitted <==

----- Start of picture text -----

Annakim Biosciences
zacharon
pharmaceutical
s
----- End of picture text -----

==> picture [18 x 37] intentionally omitted <==

==> picture [201 x 31] intentionally omitted <==

Representative Clients Small & Mid Size Biotech/ Specialty Pharm

==> picture [9 x 14] intentionally omitted <==

==> picture [34 x 14] intentionally omitted <==

==> picture [10 x 14] intentionally omitted <==

==> picture [20 x 14] intentionally omitted <==

==> picture [162 x 37] intentionally omitted <==

==> picture [144 x 43] intentionally omitted <==

==> picture [29 x 38] intentionally omitted <==

==> picture [67 x 34] intentionally omitted <==

==> picture [181 x 42] intentionally omitted <==

==> picture [127 x 31] intentionally omitted <==

==> picture [145 x 26] intentionally omitted <==

==> picture [244 x 19] intentionally omitted <==

==> picture [129 x 36] intentionally omitted <==

==> picture [110 x 27] intentionally omitted <==

==> picture [256 x 32] intentionally omitted <==

==> picture [46 x 46] intentionally omitted <==

==> picture [92 x 52] intentionally omitted <==

==> picture [66 x 12] intentionally omitted <==

----- Start of picture text -----

KisoJi
----- End of picture text -----

==> picture [184 x 27] intentionally omitted <==

==> picture [127 x 53] intentionally omitted <==

==> picture [93 x 31] intentionally omitted <==

==> picture [123 x 41] intentionally omitted <==

==> picture [59 x 55] intentionally omitted <==

==> picture [92 x 27] intentionally omitted <==

==> picture [153 x 45] intentionally omitted <==

==> picture [364 x 142] intentionally omitted <==

----- Start of picture text -----

Health Ever Biotech
----- End of picture text -----

==> picture [132 x 58] intentionally omitted <==

==> picture [106 x 28] intentionally omitted <==

==> picture [123 x 46] intentionally omitted <==

==> picture [63 x 76] intentionally omitted <==

==> picture [96 x 33] intentionally omitted <==

==> picture [106 x 53] intentionally omitted <==

==> picture [121 x 35] intentionally omitted <==

==> picture [92 x 34] intentionally omitted <==

==> picture [152 x 45] intentionally omitted <==

==> picture [110 x 35] intentionally omitted <==

Representative Clients Gov’t & Non-Gov’t Organizations

==> picture [91 x 29] intentionally omitted <==

==> picture [67 x 78] intentionally omitted <==

==> picture [137 x 65] intentionally omitted <==

==> picture [99 x 20] intentionally omitted <==

==> picture [66 x 64] intentionally omitted <==

==> picture [70 x 49] intentionally omitted <==

==> picture [71 x 70] intentionally omitted <==

==> picture [82 x 52] intentionally omitted <==

==> picture [68 x 65] intentionally omitted <==

==> picture [103 x 34] intentionally omitted <==

==> picture [83 x 31] intentionally omitted <==

==> picture [68 x 62] intentionally omitted <==

==> picture [91 x 39] intentionally omitted <==

==> picture [115 x 38] intentionally omitted <==

Representative Clients Investors

==> picture [134 x 31] intentionally omitted <==

==> picture [244 x 43] intentionally omitted <==

==> picture [91 x 62] intentionally omitted <==

==> picture [139 x 57] intentionally omitted <==

==> picture [114 x 41] intentionally omitted <==

==> picture [84 x 48] intentionally omitted <==

Working With Numerous Investors

• A.M. Pappas & Associate

• Hercules Technology

• ABV • Horizon Technology • Accelerator Finance • Actin Biomed • Innovis • • Aisling Capital J & J Ventures (JJDC) • • Alafi Capital JMP Securities • Alexandria • JP Morgan • Alix Partners • Lilly Ventures • • Amgen Ventures Lumira Capital • Arch • MedImmune Ventures • Atlas Venture • MPM • • Bay City Capital Novartis Bioventure Fund • • Biotechnology Value Fund Novo Ventures • CMEA • Oxford Finance Corp. • De Novo Ventures • Pacific Growth Equities • DiBari Group • Panorama Capital • EDB (Singapore) • EQT • Flagship Ventures • Gamma Capital Partners

• Paramount BioCapital • Paul Capital Partners • Prospect Venture Partners • Puretech Ventures • RCT • Science Futures • Seven Hills • SG Cowen • Soffinova • SR One • SV Life Sciences • SVB • Thomas McNerney Partners • TPG Ventures • USVP • Versant Ventures

Existing Network Of World Class Institutions & Partners

==> picture [626 x 281] intentionally omitted <==

----- Start of picture text -----

Institutions & Government Organizations:
----- End of picture text -----

Recognized Abilities

• ✓ Nikkei article 2012 ✓ Recipient of 2 President’s Awards, Kyowa Hakko Kogyo 2005, 2007

• ✓ Nikkei article May 2007 ✓ BioCentury, “Cracking the Code” April 23, 2012 Vol 20, Number 17, pp A1 of 18.

==> picture [392 x 515] intentionally omitted <==

Solutions for Unmet Medical Needs

==> picture [226 x 88] intentionally omitted <==

Introducing VECTUS BIOSYSTEMS

==> picture [253 x 74] intentionally omitted <==

Advanced Novel Peptide Therapeutic Treatments for Diseases with High Unmet Needs

Publicly traded ASX:VBS Established Sydney, AU 2005

Company Highlights

• Robust clinical pipeline of fibrosis treatments for high unmet needs

• Accugen Technology: Next generation discovery engine utilizing epigenetics

2

www.vectusbiosystems.com.au

2

Robust VIP Pipeline

==> picture [923 x 439] intentionally omitted <==

----- Start of picture text -----

Preclinical IND Phase 1 Phase 2
VB0004 Myocardial & Renal Fibrosis (including TTR-CM/CF) * Orphan Designation
VB0004 Pulmonary Fibrosis
VB4-A32 Liver Fibrosis
Pulmonary Fibrosis,
VB4-A79
Blood Pressure
VB4-P5 Renal Antifibrotic Orphan Indication
3
----- End of picture text -----*

Cardiovascular Diseases Represent the Leading Cause of Death Worldwide, Accounting for Nearly 18 Million Deaths Annually

The development of myocardial fibrosis associated with all cardiovascular disease, representing pathological changes that correspond with worsened clinical outcomes

4

Treatment Challenges Present Large Economic Burden

Heart disease remains the predominant cause of mortality in the United States, accounting for nearly 800,000 deaths per year.

PRESENTS A CONSIDERABLE ECONOMIC BURDEN

==> picture [411 x 119] intentionally omitted <==

----- Start of picture text -----

2011: Predicted Rising Costs 2030:
USD 320 Billion USD 918 Billion
----- End of picture text -----

==> picture [427 x 240] intentionally omitted <==

Despite substantial improvements in therapeutic strategies, cardiovascular disease remains the leading cause of death worldwide . indicating an urgent need for innovative treatment strategies

Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation . 2015; 131 :e29–e322. doi: 10.1161/CIR.0000000000000152.

5

VB0004: Novel, FirstIn-Class VIP Agonist for Treatment of Myocardial & Renal Fibrosis Replenishing VIP in Tissue